- Details
- Deepak Kilari discusses a Phase II trial exploring the combination of enzalutamide with five alpha-reductase inhibitors (ARIs) for castrate-sensitive prostate cancer. Driven by observations from geriatric oncology, the study seeks alternatives to androgen deprivation therapy (ADT) for older, frail men who struggle with its side effects. The trial examines whether enzalutamide combined with dutaste...
|
- Details
- Scott Tagawa discusses the final results of a phase I/II trial exploring dose-escalation of lutetium PSMA for advanced prostate cancer. Launched in 2017, this trial aimed to determine the safety and efficacy of increasing radioactive doses in a fractionated, dose-dense regimen to maintain constant tumor exposure. The study escalated doses from 7.4 to 22.2 gigabecquerels without reaching a dose-lim...
|
- Details
- Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to evaluate how well Veterans understand and make decisions about genetic testing. Initial interviews with 31 patients reveal that most found the decision straightforward, but some had uncertainties about the im...
|
- Details
- Zach Klaassen discusses the ARASTEP trial with Alex Chehrazi-Raffle. The trial focuses on patients with high-risk biochemical recurrence of prostate cancer, specifically those who show positive results on PSMA PET scans but are negative on conventional imaging. Dr. Chehrazi-Raffle explains that ARASTEP, a randomized phase 3 study, aims to evaluate the efficacy of combining androgen deprivation the...
|
- Details
- Zach Klaassen and Benjamin Maughan discuss new insights into the real-world application of apalutamide in treating metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Maughan highlights the significance of achieving deep PSA responses as a key prognostic marker for patient outcomes. The OASIS project, utilizing data from diverse medical settings across the U.S., demonstrates that patients wh...
|
- Details
- Alicia Morgans speaks with Dan Petrylak about his phase 1 study on a new androgen receptor (AR) degrader, ARV-766. This study explores the potential of AR degraders to effectively target and dismantle androgen receptors in prostate cancer cells, particularly those resistant to conventional therapies. Dr. Petrylak highlights the journey of ARV-766, a second-generation PROTAC drug designed to degrad...
|
- Details
- Alicia Morgans sits down with Christos Kyriakopoulos to discuss the findings from the CHAARTED 2 trial. This study builds on the success of the original CHAARTED trial, focusing on combining standard therapies with second-line chemotherapy to improve outcomes for patients with metastatic castration-resistant prostate cancer. Initiated in 2018 and completed amid the challenges of the COVID-19 pande...
|
- Details
- Susan Halabi discusses her presentation on prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) based on the Alliance trial. The phase three trial, which enrolled 1,311 patients, compared the effects of enzalutamide alone to enzalutamide combined with abiraterone and prednisone. Despite no difference in overall survival between the treatment arms, Dr. Halabi's team develop...
|
- Details
- Phillip Koo interviews Wolfgang Fendler about advancements in PSMA PET imaging and its prognostic capabilities. Dr. Fendler highlights that the PROMISE criteria, developed for standardized PSMA PET reporting, now show significant prognostic value in predicting overall survival in prostate cancer across all stages. His team’s research demonstrates that metrics like total tumor volume and average PS...
|
- Details
- Michael Morris shares insights into his presentation on a novel hK2-targeting antibody radioconjugate, JNJ-6420, which uses an actinium radioisotope. Dr. Morris explains that hK2, akin to PSA, binds to prostate cancer cell membranes, making it an ideal target for this radioligand therapy. Unlike existing beta emitters, this alpha-emitting treatment delivers intense, localized radiation, promising...
|
